Edition:
United States

Cellectis SA (ALCLS.PA)

ALCLS.PA on Paris Stock Exchange

21.37EUR
22 Mar 2017
Change (% chg)

-- (--)
Prev Close
€21.37
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
113,664
52-wk High
€30.14
52-wk Low
€14.08

Latest Key Developments (Source: Significant Developments)

Servier, Pfizer announce FDA clearance of IND application for UCART19
Thursday, 9 Mar 2017 02:04am EST 

Pfizer Inc : Servier and Pfizer announce FDA clearance of IND application for UCART19 in adult relapsed/refractory acute lymphoblastic leukemia .Pfizer inc - U.S. FDA has granted Servier with an investigational new drug clearance to proceed in U.S. With clinical development of UCART19.  Full Article

Cellectis SA reports fourth quarter results
Monday, 6 Mar 2017 04:30pm EST 

Cellectis SA : Cellectis reports 4th quarter and full year 2016 financial results . Cellectis SA - revenues and other income of $56 million in 2016 . Cellectis SA - during quarters ended december 31, 2015 and 2016, recorded eur29.2 million and eur12.1 million, respectively, in revenues and other income . Cellectis SA - during quarters ended december 31, 2015 and 2016, recorded a net gain of eur8.2 million and net loss of eur12.5 million .Cellectis SA - adjusted income attributable to shareholders of cellectis for q4 was eur0.6 million versus eur20.9 million.  Full Article

FDA grants Cellectis IND approval to proceed with development of UCART123
Monday, 6 Feb 2017 04:30pm EST 

Cellectis SA : FDA grants cellectis IND approval to proceed with the clinical development of UCART123, the first gene edited off-the-shelf car t-cell product candidate developed in the U.S. .Intends to initiate phase 1 trials in first half of 2017.  Full Article

Cellectis submits IND application for UCART123
Tuesday, 3 Jan 2017 05:00pm EST 

Cellectis Sa : Cellectis submits IND application for UCART123, an allogeneic gene edited car t-cell product candidate, in AML and BPDCN .Cellectis sa says pending regulatory clearance, plans to initiate phase 1 clinical trials in first half of 2017.  Full Article

Cellectis Announces the Issuance of US Patent 9,458,439
Wednesday, 5 Oct 2016 02:03am EDT 

Cellectis SA : Announced on Tuesday the issuance of U.S. patent 9,458,439 – which claims gene inactivation by use of chimeric restriction endonucleases .This patent granted by the USPTO to the Institut Pasteur and Boston Children's Hospital naming Dr Andre Choulika and Pr. Richard C. Mulligan as co-inventors, is exclusively licensed to Cellectis.  Full Article

Cellectis says first patient treated in phase 1 trial of UCART19
Monday, 20 Jun 2016 05:00pm EDT 

Cellectis SA : Cellectis SA says first patient treated in phase 1 trial of ucart19 in pediatric acute B lymphoblastic leukemia . Cellectis announces first patient treated in phase 1 trial of ucart19 in pediatric acute b lymphoblastic leukemia (b-all) .Announces First Patient Treated In Phase 1 Trial Of Ucart19 In Pediatric Acute B Lymphoblastic Leukemia (B-all).  Full Article

Cellectis Q1 net result turns to loss of 6.3 million euros
Thursday, 12 May 2016 02:59am EDT 

Cellectis : Reported on Wednesday Q1 revenue of 7.0 million euros vs 8.4 million euros last year . Q1 net loss is 29.5 million euros vs profit of 6.3 million euros last year .Expected that its cash, cash equivalents and Current financial assets of 276.5 million euros as of March 31 will be sufficient to fund its current operations through 2018.  Full Article

Cellectis reports first quarter 2016 financial results
Wednesday, 11 May 2016 05:00pm EDT 

Cellectis Sa :Cellectis reports first quarter 2016 financial results.  Full Article

Cellectis SA announces RetroNectin supply and license agreement with Takara Bio Inc
Monday, 21 Mar 2016 05:00pm EDT 

Cellectis SA:Has entered into a supply and license agreement with Takara Bio Inc for recombinant human fibronectin fragment RetroNectin.Financial terms of the agreement are not disclosed.  Full Article

Cellectis and MabQuest announce immunotherapy partnership
Tuesday, 15 Mar 2016 08:00pm EDT 

Cellectis SA:Announced an immunotherapy partnership with MabQuest on new class of PD-1 antagonist monoclonal antibodies.  Full Article

More From Around the Web

BRIEF-FDA grants Cellectis IND approval to proceed with development of UCART123

* FDA grants cellectis IND approval to proceed with the clinical development of UCART123, the first gene edited off-the-shelf car t-cell product candidate developed in the U.S.